Cart
sales@molnova.com
Nemvaleukin alfa
CAS No. 2315268-27-8
Nemvaleukin alfa( —— )
Catalog No. M36815 CAS No. 2315268-27-8
Nemvaleukin alfa (ALKS 4230) is an interleukin 2 fusion protein, a selective agonist of the medium-affinity IL-2 receptor, produced by fusion of the IL-2Ralpha subunit of the circularly arranged interleukin-2 (IL-2) and IL-2 receptor (IL-2R) complexes, which drives antitumor Immunity and inhibits tumor growth in small cell lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 628 | Get Quote |
|
| 5MG | 1017 | Get Quote |
|
| 10MG | 1634 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNemvaleukin alfa
-
NoteResearch use only, not for human use.
-
Brief DescriptionNemvaleukin alfa (ALKS 4230) is an interleukin 2 fusion protein, a selective agonist of the medium-affinity IL-2 receptor, produced by fusion of the IL-2Ralpha subunit of the circularly arranged interleukin-2 (IL-2) and IL-2 receptor (IL-2R) complexes, which drives antitumor Immunity and inhibits tumor growth in small cell lung cancer.
-
DescriptionNemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer.
-
In Vitro——
-
In VivoAnimal Model:SCLC orthotopic model Dosage:6 mg/kg Administration:s.c., every 4?days Result:Delayed tumor growth and prolonged survival. Animal Model:Male cynomolgus monkeys (PK Assay) Dosage:0.3 or 1 mg/kg Administration:i.v. or s.c.Result:Pharmacokinetic profile of Nemvaleukin alfa.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorInterleukin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2315268-27-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pan Y, et al, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913. ?
molnova catalog
related products
-
ELOVL1-IN-1
ELOVL1-IN-1 is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).
-
Copper(II) D-glucona...
Copper(II) D-gluconate powder in combination with silicon was used for the fabrication of carbon coated Si-Cu3Si composite as the anode materials for Li-ion batteries.
-
S0859
S0859, an N-cyanosulphonamide compound, reversibly inhibit NBC-mediated pH(i) recovery.
